KLK4 and ovarian carcinoma: In this study, we investigated the serum levels of kallikreins 5, 6, 7, 8, 10 and 11 in relation to the clinical response of ovarian cancer patients to chemotherapy, the survival outcome (overall and progression-free survival), as well as the time to progression (TTP) of the disease.